Compare Stanley Black & Decker, Inc. (SWK) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stanley Black & Decker, Inc. vs BIO-TECHNE Corp — how do they compare? Stanley Black & Decker, Inc. trades at $87.62 (market cap $13.60B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Stanley Black & Decker, Inc. is the larger of the two by market cap, and Stanley Black & Decker, Inc. pays the higher dividend (3.79%). Which is the better fit depends on your goals.
| SWK | TECH | |
|---|---|---|
Market Cap | $13.60B | $11.16B |
52-Week High | $94.12 | $72.12 |
52-Week Low | $62.12 | $43.31 |
Enterprise Value | $19.77B | $11.24B |
Dividend Yield | 3.79% | 0.45% |
Sector | — | Health |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
